Behcet Disease-associated Uveitis Successfully Treated with Golimumab

Over the past decade, the off-label use of biologic agents such as TNF-alpha antagonists, including infliximab and adalimumab, has improved the treatment armamentarium for refractory immune-mediated uveitis, with particular success in Behcet disease-associated uveitis. Golimumab is a novel fully human anti-TNF-alpha monoclonal antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with very promising results. Herein, the authors present the use of GLM in a case of Behcet uveitis refractory to other TNF-alpha blockers. There are only two reports in the literature about the use of GLM in uveitis, describing four patients with JIA-associated uveitis and a case of idiopathic retinal vasculitis. To the authors' knowledge, this is the first report about the use of GLM in Behcet uveitis.